Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Structure Therapeutics Inc. GPCR NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
59/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$116.71
+119.4%

Structure Therapeutics Inc. (GPCR) is a Biotechnology company in the Healthcare sector, currently trading at $53.19. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is GPCR = $117 (+119.4% upside).

Valuation: GPCR trades at a trailing Price-to-Earnings (P/E) of -22.5 (S&P 500 average ~25).

Net income is $141M (loss), growing at -42.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $6M against $1.5B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 24.81 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $1.6B.

Analyst outlook: 14 / 14 analysts rate GPCR as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$116.71
▲ 119.4% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Structure Therapeutics Inc., the average price target is $116.71, with a high forecast of $145.00, and a low forecast of $90.00.
Highest Price Target
$145.00
Average Price Target
$116.71
Lowest Price Target
$90.00

GPCR SharesGrow Score Overview

71/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GPCR

✓
VALUE Pass
100/100
GPCR trades at a trailing Price-to-Earnings (P/E) of -22.5 (S&P 500 average ~25). Forward PEG -0.35 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $117, implying +119.9% from the current price $53. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GPCR: +0%/yr revenue is, -42.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet GPCR: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 24.81 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
GPCR: Gross margin is 0% (+0 pp trend), $3B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 14 / 14 analysts rate GPCR as buy (100%). Analyst consensus target is $117 (+119.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range13.22-94.9
Volume1.04M
Avg Volume (30D)1M
Market Cap$3.06B
Beta (1Y)-1.25
Share Statistics
EPS (TTM)-2.40
Shares Outstanding$59.2M
IPO Date2023-02-03
Employees163
CEORaymond C. Stevens
Financial Highlights & Ratios
Gross Profit$-3.9M
EBITDA$-136.79M
Net Income$-141.2M
Operating Income$-287.57M
Total Cash$1.45B
Total Debt$6.49M
Net Debt$-793.14M
Total Assets$1.58B
Price / Earnings (P/E)-22.2
Analyst Forecast
1Y Price Target$125.00
Target High$145.00
Target Low$90.00
Upside+135.0%
Rating ConsensusBuy
Analysts Covering14
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS86366E1064

Price Chart

Track all markets on TradingView
GPCR
Structure Therapeutics Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
13.22 52WK RANGE 94.90

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 MORF
MORF
Morphic Holding, Inc.
$56.99
+0.04%
 IRON
IRON
Disc Medicine, Inc.
$70.48
+2.95%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.20
-0.62%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message